AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2021

Feb 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-02-14

Reporting Person: Bowden Christopher (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-14	Common stock	M	4000	—	Acquired	12381	Direct
2021-02-16	Common stock	M	2750	—	Acquired	15131	Direct
2021-02-16	Common stock	F	2069	—	Disposed	13062	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-14	Restricted stock units	$	M	4000	Disposed		Common stock (4000.0)	Direct
2021-02-16	Restricted stock unit	$	M	2750	Disposed		Common stock (2750.0)	Direct

Footnotes

F1: Includes 75 shares purchased through the Company's employee stock purchase plan.

F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments.

F4: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments.